Please assess the completion status of the following clinical trial:

Trial Title: Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75~* History of acromegaly with biochemical cure documented with a normal oral glucose tolerance test (OGTT) and/or a non-elevated IGF-I without concurrent use of somatostatin analogs, dopamine agonists or GH receptor antagonists. Subjects will have been treated with medication, surgery, radiation, or a combination of these~* At the time of enrollment a minimum of 6 months must have elapsed since surgery.~* No malignancy on colonoscopy performed since the diagnosis of acromegaly~* GHD due to surgical or radiation treatment~* GHD will be defined as a peak plasma GH of less than 5 ng/ml in response to an insulin tolerance test or a GH-releasing hormone (GHRH) plus arginine stimulation test~* GHD will also be diagnosed if IGF-I levels are below 2 standard deviations for the age-sex normal range in a patient with at least two other documented anterior pituitary hormone deficiencies~Exclusion Criteria:~* Untreated thyroid or adrenal insufficiency. Subjects on replacement therapy must be stable for at least 3 months prior to entry into the study~* History of malignancy except for non-melanoma skin cancer~* Hemoglobin \<11.0 gm/dl~* Uncontrolled hypertension~* Hepatic or renal disease (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3x upper limit of normal (ULN) or creatinine level \>2.5 mg/dl)~* Congestive heart failure (New York Heart Association's classification system Class II-IV congestive heart failure (CHF) will be excluded)~* Unstable cardiovascular disease (coronary artery or cerebrovascular disease) or symptoms within one year prior to entry into the study~* Initiation or discontinuation of gonadal steroid therapy within 3 months of entry~* Diabetes mellitus, impaired fasting glucose, impaired glucose tolerance~* Pregnancy or nursing~* Active carpal tunnel syndrome~* Subjects who have received GH therapy within one year prior to entry into the study~* For female subjects age \>40 a screening mammogram must have been obtained within one year prior to their baseline visit.~* Sensitivity to m-cresol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- AcroGHD Randomized to Growth Hormone (Type: ACTIVE_COMPARATOR): Subjects with a history of acromegaly who are now growth hormone deficient, randomized to growth hormone. This is an interventional arm.
- AcroGHD Randomized to Placebo (Type: PLACEBO_COMPARATOR): Subjects with a history of acromegaly who are now growth hormone deficient, randomized to placebo. This is an interventional arm.
- AcroGHS (Type: NO_INTERVENTION): None
- Active Acromegaly (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).